Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: CNS Drugs. 2012 Aug 1;26(8):707–716. doi: 10.2165/11634260-000000000-00000

Table III.

Univariate and multivariate analyses of adverse events in conversion and control period (n = 1092)

Adverse event Conversion period
Control period
p-Value Adjusted odds ratio 95% CI p-Value
n % n %
All-cause ED 93 15.1 80 13.0 0.23 1.35 0.92, 1.97 0.13
All-cause hospital 18 2.9 15 2.4 0.59 1.21 0.60, 2.46 0.59
All-cause ED/hospital 98 15.9 89 14.4 0.41 1.16 0.81, 1.67 0.41
Epilepsy ED/hospital 12 1.9 10 1.6 0.64 1.25 0.49, 3.17 0.64
Condition-related ED/hospital 27 4.4 19 3.1 0.21 1.75 0.87, 3.51 0.12
All-cause ED/hospital
 Epilepsy (n = 255) 46 18.0 44 17.3 0.80 1.07 0.64, 1.81 0.79
 Non-epilepsy (n = 361) 52 14.4 45 12.5 0.38 1.68 0.95, 2.98 0.08

ED = emergency department.